|Bid||0.00 x 800|
|Ask||0.00 x 1300|
|Day's range||69.52 - 74.58|
|52-week range||69.52 - 221.00|
|Beta (5Y monthly)||1.52|
|PE ratio (TTM)||N/A|
|Earnings date||23 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||74.71|
Tuesday morning, global financial services mainstay HSBC Holdings initiated coverage on Beyond Meat shares. The company probably wishes the bank hadn't; analyst Jeremy Fialko put a reduce (sell) tag on the stock, at a $62 per share price target. Both privately held up-and-comers like Impossible Foods and publicly traded comestibles majors such as Tyson Foods have developed meat alternatives with a range of products.
Yahoo Finance Live discusses U.S. plant-based meat sales declining as low as 0.6% in 2021.
Investing in stocks that are falling can be tough to do; nobody wants to look at their portfolio and see red. Shares of COVID-19 vaccine-maker AstraZeneca are down 5% over the past three months, while the S&P 500 has soared by more than 5%. Up until now, AstraZeneca hasn't been trying to make a profit from its COVID-19 vaccine.